Diverse biomarkers, including PSA, BRCA mutations, PSMA, and AR-V7, guide treatment decisions in advanced prostate cancer management. Emerging biomarkers like ctDNA and PTEN loss offer predictive and ...

“Especially as MRI advanced, so not all elevated PSA automatically meant a biopsy.” Based on the increase in prostate cancer cases across all ages, Siegel emphasized the need to “diagnose it ...

Prostate cancer is a type of malignancy that arises in the prostate gland. Prostate cancer tends to develop in older men, aged 50 and over. In many cases prostate cancer develops slowly, although ...

The incidence of late grade 2 or greater GU toxicity at 5 years was 12.5% among those who did experience acute toxicity vs 7.5% among those who did not. “MPS2 could potentially improve the health of ...